Description
Y-shapePEGNHSEster withsuperiorqualityspecificationof ≥95%Substitution.
Y-shapePEGNHS fromJenKemTechnologyisaSuccinimidylCarboxymethylEsterbranched2ARMPEG,reactivetowardstheaminogroupoflysine(s)onproteinsorotherBIOLOGics.AminePEGylationwithY-shapePEGNHScanbecompletedinlessthan1hratpH7-8.JenKemproprietaryY-shapePEGsaremoreselective,duetotheirstericallybulkystructure.PleasereviewtheapplicationnoteforthisproductforadditionalinstructionsforaminePEGylationwithY-NHS-40K.
SchematicofProteinPEGylationwithJenKem®Y-PEG-NHS
JenKemTechnologyoffers Y-shapePEGNHS withMW40000,in1gand10gpackingsizes. JenKemTechnology providesrepackagingservicesforanadditionalfee,pleasecontactusifyourequireadifferentpackagesizethanourcatalogselection.
DifferentMWof Y-shapePEGNHS productsmaybeavailablebycustomsynthesis,pleaseemailus attech@jenkemusa.comfordetailsoncustomPEGs.
BulkPEGsandGMPgradePEGsaremade-to-order.Please contactus forbulkpricing.
ApplicationofY-NHS-40KforPEGylation:
| DrugMoleculeorOtherEntityPEGylatedwithY-NHS-40K | References |
| Calciumphosphatenanoparticles | 7 |
| Cp40 | 4 |
| DNAaptamer(SOMAmer) | 2 |
| G-CSF | 15 |
| Gentamicin | 14 |
| IFN-α2a | 16 |
| IFN-α2b | 17 |
| LIFreceptorantagoNIST(LA) | 11 |
| L-RNA(Spiegelmer) | 5 |
| L-RNA(Spiegelmer) | 8 |
| rhGH | 18 |
| TNF-α | 9,10 |
ClickheretodownloadtheMSDS
References:
1.AlQahtani,A.D.,etal.,Productionof“biobetter”glucarpidasevariantstoimprovedrugdetoxificationandantibodydirectedenzymeprodrugtherapyforcancertreatment,EuropeanJournalofPharmaceuticalSciences,2019,127,P.79-91.
2.Haruta,K.,etal.,ANovelPEGylationMethodforImprovingthePharmacokineticPropertiesofAnti-Interleukin-17ARNAAptamers,Nucleicacidtherapeutics,2017,27(1):36-44.
3.Guo,L.,etal.,ApplicationInstructionsforY-NHS-40KforAminePEGylation,click link.
4.Masao,H.,etal.,ChemicallyModifiedInterleukin-6AptamerInhibitsDevelopmentofCollagen-InducedArthritisinCynomolgusMonkeys,NucleicAcidTherapeutics,2015.
5. Winship,A.L.,Interleukin-11altersplacentationandcausespreeclampsiafeaturesinmice,ProcNatlAcadSciUSA.,2015,112(52):15928-33.
6. ,A.M.,etal., PeptideinhibitorsofC3activationasanovelstrategyofcomplementinhibitionforthetreatmentofparoxysmalnocturnalhemoglobinuria, BloodMar,2014,123(13)2094-2101.
7.Roccaro,Aldo M.etal., SDF-1InhibitionTargetstheBoneMarrowNicheforCancerTherapy, CellReports,2014,9(1),p:118–128.
8. Stefan,N.,etal.,NovelProdrug-LikeFusionToxinwithProtease-SensitiveBioorthogonalPEGylationforTumorTargeting,Bioconjugatechemistry, 2014,25.12:2144-2156.
9.Ashokan,A.,etal.,Multifunctionalcalciumphosphatenano-contrastagentforcombinednuclear,magneticandnear-infraredin vivoimaging.Biomaterials,2013,34(29):p.7143-7157.
10.Khan,M.A.,etal., Targetingcomplementcomponent5apromotesvascularintegrityandlimitsairwayremodeling,PNAS,2013,110(15)p:6061-6066.
11. Dai,C.Y., etal.,PreparationandevaluationofanewreleasablePEGylatedtumornecrosisfactor-α(TNF-α)conjugatefortherapeuticapplication,ScienceChinaLifeSciences,2013,56.1:51-58.
12.Dai, C.Y.,etal., LinkagewithcathepsinB-sensitivedipeptidepromotestheinvitroandinvivoanticanceractivityofPEGylatedtumornecrosisfactor-alpha(TNF-α)againstmurinefibrosarcoma, ScienceChinaLifeSci,2011,54(2):128–138.
13. Menkhorst,E.,etal.,VaginallyAdministeredPEGylatedLIFAntagonistBlockedEmbryoImplantationandEliminatedNonTargetEffectsonBoneinMice,PLoSONE, 2011,6(5)e19665.
14. Cai,Y.,etal.,Separationofexenatideanaloguemono-PEGylatedwith40kDApolyethyleneglycolbycationexchangechromatography,JournalofChromatographyA,2011,1218:39,P.6953-6960.
15. Wang,Y-J.,etal.,PEGylationmarkedlyenhancestheinvivopotencyofrecombinanthumannon-glycosylatederythropoietin:Acomparisonwithglycosylatederythropoietin,JournalofControlledRelease, 2010,145:3,p. 306-313.
16.Marcus,Y.,etal.,TurningLow-Molecular-WeightDrugsintoProlongedActingProdrugsbyReversIBLePegylation:AStudywithGentamicin, JournalofMedicinalChemistry,2008,51(14),4300-4305.
17.Wang,S.,etal.,Y-typepolyethyleneglycolmodifiedG-CSFandpreparationmethodandusethereof.PatentCN200780051378,2007.
18.Zhou,W.,etal.,Interferonalpha2amodifiedbypolyethyleneglycol,itssynthesisprocessandapplication.PatentCN200780050541,2007.
19.Zhou,W.,etal.,Interferonalpha2bmodifiedbypolyethyleneglycol,itssynthesisprocessandapplication.PatentCN200780050542,2007.
20.Zhou,W.,etal.,Double-strandedpolyethyleneglycolmodifiedgrowthhormone,preparationmethodandapplicationthereof.PatentCN200880009718,2008.
Foundedin2001byexpertsinPEGsynthesisandPEGylation,JenKemTechnologyspecializesexclusivelyinthedevelopmentandmanufacturingofhighqualitypolyethyleneglycol(PEG)productsandderivatives,andrelatedcustomsynthesisandPEGylationservices.JenKemTechnologyisISO9001andISO13485certified,andadherestoICHQ7AguidelinesforGMPmanufacture.TheproductionofJenKem®PEGsisback-integratedtoin-housepolymerizationfromethyleneoxide,enablingfaciletraceABIlityforregulatedcustomers.JenKemTechnologycaterstothePEGylationneedsofthepharmaceutical,biotechnology,medicaldeviceanddiagnostics,andemergingchemicalspecialtymarkets,fromlaboratoryscalethroughlargecommercialscale.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
小弟有一中药处方，需要水煮醇沉处理，问下具体该怎么做，给我方子的老师去世了
告诉我中药先水煮，在用水煮醇沉法外敷治疗
给电话我直接问液可以
各位老师好,有做环黄芪醇的吗?其对心血管效果怎么样?使用剂量范围是不是很窄,我看文献,有报道,黄芪提取物对血管的作有是双向的,会不会在低剂量时对身体是有害的
完全醇水溶液如长期存放，会出现粘度增加甚至凝胶化的现象，聚合度和粘度越高，储存温度越低，越容易出现这种想象。可以采取以下措施：
（1）将聚乙烯醇水溶液重新加热搅拌即可恢复原来的流动性。
（2）添加硫氰盐酸盐（如钙、钠、铵等盐类）、苯酚、丁醇、山梨酸等可以有效防止凝胶化，添加量为5~10%。部分醇解型PVA长期存放不易产生粘度增加的情况。同时要注意长期存放容易发生发霉、腐化现象，需添加防霉、防腐剂。建议配置好水溶液后即时使用。
在本例中，溴处在间位，因此不参与反应。
而氯恰好处于对位，因而能发生反应，被甲氧基取代。
因此产物是4-硝基-2-溴苯甲醚。
各位亲，本人用70%乙醇回流提了中药大概70L，准备旋蒸浓缩但一直没浓缩，室温放了5天，之后要做药理试验的，会不会影响药效？需要重提吗？感谢感谢
（二）连接回流冷凝管时，冷凝管连接水不会对浸出物造成影响吗？
请求大神指点，不胜感激！
本人目前在做一个中药提取方法的研究，水提醇沉，醇沉浓度分别为50%、60%和70%,检验结果，得率分别为21.99%、23.85%和25.55%，但含量分别是33.48mg/g、16.60mg/g和19.42mg/g。理论上是醇沉浓度越高，去除的杂质越多，得率越低吗？含量是不是也应该是醇沉浓度越高含量越高？我的试验有什么问题，求各位大虾指点！
我想提取中药中的有效成分，好像目前醇提取的比较多，中药有比如黄柏，桑白皮这些。有谁知道醇提取步骤吗？能不能帮帮忙，万分感激
补充：
一般使用浓硫酸作催化剂，使醇类脱去羟基生成含双键的有机物。应注意的是醇发生消去反应时的温度控制，温度较低(140℃)时会生成副产物醚类，温度达到一定范围（170℃）时才会发生消去反应。消去反应的本质是羟基与β位上的一个H原子共同脱去生成H2O的反应，因而能发生消去反应的醇类必须要有β-H原子。
如果羟基相连接的碳的邻位碳有多个，且都有氢原子，则消去有氢原子较少的邻位碳上的氢原子。 示例：
乙醇发生消去反应的方程式
CH3CH2OH→CH2=CH2+H2O （条件为浓硫酸 170摄氏度）
求助战友们：
有做过中药醇提取，但是在收醇的时候，当浓缩至醇浓度约20%的时候，有析出现象，析出的还是我的有效成分，怎么才能解决这个问题呢？如果在未析出时停止浓缩，药液太稀，无法干燥呢？
问题1：我该如何浓缩定参数？
问题2：如果在未析出时放液，由于药液太稀，我该如何选择干燥方式？
求助站里的大侠们，谢谢！
